February 10, 2022
On January 27th, ASBM joined other patient advocacy organizations and physician groups in submitting a coalition letter to the U.S. Department of Health and Human Services (HHS), urging the Department to prohibit the practice of copay accumulator adjustment policies. The coalition letter was submitted as part of the comment period on the HHS Notice of Benefit and Payment Parameters […]
February 10, 2022
On January 27th, ASBM joined other patient advocacy organizations and physician groups in submitting a coalition letter to the U.S. Department of Health and Human Services (HHS), urging the Department to prohibit the practice of copay accumulator adjustment policies. The coalition letter was submitted as part of the comment period on the HHS Notice of Benefit and Payment Parameters […]
February 3, 2022
From March 9-11, ASBM will participate in the Festival of Biologics USA 2022, held in San Diego, California. Two ASBM representatives will be presenting on a variety of topics, and moderating several discussion panels at the three-day conference. On March 9th, ASBM Advisory Board Chair Philip Schneider will give a Plenary Presentation on the current biosimilars landscape, […]
February 3, 2022
On January 25th, ASBM’s Immediate Past Chair Madelaine Feldman, MD FACR participated in a webinar entitiled “What’s the Hold-Up? Overcoming Barriers to the Use of Biosimilars,” hosted by The Center for Biosimilars. At the forum, Dr. Feldman discussed the role of payers like insurance companies and pharmacy benefit managers (PBMs) in contributing to higher drug […]
February 3, 2022
On January 25th, ASBM’s Immediate Past Chair Madelaine Feldman, MD FACR participated in a webinar entitiled “What’s the Hold-Up? Overcoming Barriers to the Use of Biosimilars,” hosted by The Center for Biosimilars. At the forum, Dr. Feldman discussed the role of payers like insurance companies and pharmacy benefit managers (PBMs) in contributing to higher drug […]
January 30, 2022
On December 9th, ASBM participated in the 16th Biosimilar Congregation, which focused on the Indian biosimilars market. By 2030, India is expected to become the sixth-largest market for pharmaceuticals, and has already firmly established itself in the global biopharmaceutical market. Many Indian pharmaceutical companies are preparing to step into the global biosimilars market. ASBM was […]
January 30, 2022
On December 9th, ASBM participated in the 16th Biosimilar Congregation, which focused on the Indian biosimilars market. By 2030, India is expected to become the sixth-largest market for pharmaceuticals, and has already firmly established itself in the global biopharmaceutical market. Many Indian pharmaceutical companies are preparing to step into the global biosimilars market. ASBM was […]
January 30, 2022
On December 2nd, ASBM sent a letter to House leaders reiterating our opposition to a proposal that would undermine the patient-physician relationship and distort the making of treatment decisions. The U.S. House of Representatives Committee on Rules has released new language for H.R. 5376 containing a provision that would pay physicians a 33% bonus for prescribing their […]
January 3, 2022
The Ohio State University College of Pharmacy is now offering a second 1-hour Continuing Education (CE) course presented by OSU professor and ASBM Advisory Board Chair Philip Schneider, FASHP, FFIP. The course is entitled “Biosimilar Substitution and Interchangeability”, and discusses how biosimilars are substituted at the pharmacy level in the U.S., and contrasts U.S. practices with […]
January 3, 2022
The Ohio State University College of Pharmacy is now offering a second 1-hour Continuing Education (CE) course presented by OSU professor and ASBM Advisory Board Chair Philip Schneider, FASHP, FFIP. The course is entitled “Biosimilar Substitution and Interchangeability”, and discusses how biosimilars are substituted at the pharmacy level in the U.S., and contrasts U.S. practices with […]
